

Supporting Information

Hu et al. 10.1073/pnas.0813306106




Fig. S1. The effect of a nonspecific COX inhibitor (sulindac) on the weight of MCFDCIS xenografts derived from cells injected alone (–) or coinjected with RASFs on control or sulindac-containing diet. Sulindac attenuated the tumor growth-stimulating effects of RASFs, but this was not statistically significant ($P = 0.4$).

Mouse spleen




Fig. S3. Analysis of the presence of leukocytes in xenografts. Shown is immunohistochemical analysis of CD45 pan-leukocyte antigen expression in MCFDCIS xenografts and in mouse spleen used as positive control. Essentially no CD45+ cells are detected in the xenografts, whereas a large fraction of cells are positive for CD45 in the spleen.

Array 1

	a	b	c	d	e	f	g	h	i	j	k	l	m	n
1	POS	POS	POS	POS	Blank	Angiogenin	BDNF	BLC	BMP-4	BMP-6	CK β 8-1	CNTF	EGF	Eotaxin
2	NEG	NEG	NEG	NEG	Blank	Angiogenin	BDNF	BLC	BMP-4	BMP-6	CK β 8-1	CNTF	EGF	Eotaxin
3	Eotaxin-2	Eotaxin-3	FGF-6	FGF-7	Fil-3 Ligand	Fractalkine	GCP-2	GDNF	GM-CSF	I309	IFN-γ	IGFBP-1	IGFBP-2	IGFBP-4
4	Eotaxin-2	Eotaxin-3	FGF-6	FGF-7	Fil-3 Ligand	Fractalkine	GCP-2	GDNF	GM-CSF	I309	IFN-γ	IGFBP-1	IGFBP-2	IGFBP-4
5	IGF-1	IL-10	IL-13	IL-15	IL-16	IL-1α	IL-1β	IL-1ra	IL-2	IL-3	IL-4	IL-5	IL-6	IL-7
6	IGF-1	IL-10	IL-13	IL-15	IL-16	IL-1α	IL-1β	IL-1ra	IL-2	IL-3	IL-4	IL-5	IL-6	IL-7
7	Leptin	LIGHT	MCP-1	MCP-2	MCP-3	MCP-4	M-CSF	MDC	MIG	MIP-1β	MIP-3α	NAP-2	NT-3	PARC
8	Leptin	LIGHT	MCP-1	MCP-2	MCP-3	MCP-4	M-CSF	MDC	MIG	MIP-1β	MIP-3α	NAP-2	NT-3	PARC
9	PDGF-BE	RANTES	SCF	SDF-1	TARC	TGF-β1	TGF-β3	TNF-α	TNF-β	Blank	Blank	Blank	Blank	Blank
10	PDGF-BE	RANTES	SCF	SDF-1	TARC	TGF-β1	TGF-β3	TNF-α	TNF-β	Blank	Blank	Blank	Blank	Blank

Array 2

	a	b	c	d	e	f	g	h	i	j	k	l	m	n
1	POS	POS	POS	POS	Blank	Acnp30	AgRP	Angiopoietin-2	Amphiregulin	Axl	bFGF	b-NGF	BTC	CCL-2B
2	NEG	NEG	NEG	NEG	Blank	Acnp30	AgRP	Angiopoietin-2	Amphiregulin	Axl	bFGF	b-NGF	BTC	CCL-2B
3	CTACK	Dtk	EGF-R	ENA-78	Fas	FGF-4	FGF-9	GCSF	GITR-Ligand	GITR	GRO	GRO-α	HCC-4	HGF
4	CTACK	Dtk	EGF-R	ENA-78	Fas	FGF-4	FGF-9	GCSF	GITR-Ligand	GITR	GRO	GRO-α	HCC-4	HGF
5	ICAM-1	ICAM-3	IGFBP-3	IGFBP-6	IGF-1 SR	IL-1 R4/ST2	IL-1 RI	IL-11	IL-12 p40	IL-12 p70	IL-17	IL-2 Rα	IL-6 R	IL-8
6	ICAM-1	ICAM-3	IGFBP-3	IGFBP-6	IGF-1 SR	IL-1 R4/ST2	IL-1 RI	IL-11	IL-12 p40	IL-12 p70	IL-17	IL-2 Rα	IL-6 R	IL-8
7	I-TAC	Lymphostatin	MIF	MIP-1α	MIP-1β	MIP-3β	MSP-α	NT-4	Osteoprotegerin	Oncostatin M	PIGF	sop130	sTNF RI	sTNF-RI
8	I-TAC	Lymphostatin	MIF	MIP-1α	MIP-1β	MIP-3β	MSP-α	NT-4	Osteoprotegerin	Oncostatin M	PIGF	sop130	sTNF RI	sTNF-RI
9	TECK	TIMP-1	TIMP-2	Thrombospondin	TRAIL R3	TRAIL R4	uPAR	VEGF	VEGF-D	Blank	Blank	Blank	Blank	Blank
10	TECK	TIMP-1	TIMP-2	Thrombospondin	TRAIL R3	TRAIL R4	uPAR	VEGF	VEGF-D	Blank	Blank	Blank	Blank	Blank




Fig. S4. Analysis of conditioned media of RASFs. Maps of the 2 cytokine arrays (RayBiotech human cytokine array C series 1000) used are shown. At the bottom are results of immunoblot analysis, with the most highly positive spots marked with red circles.

Table S1. Sequences of the shRNA clones used for the study

Symbol	Clone ID	Row	Column	RNAi seq
MMP9	TRCN0000051438	C	3	CCACAACATCACCTATTGGAT
MMP9	TRCN0000051439	C	4	GCGGTGATTGACGACGCCTTT
MMP9	TRCN0000051440	C	5	CAGTACCGAGAGAAAGCCTAT
MMP9	TRCN0000051441	C	6	CAGTTTCCATTTCATCTTCCAA
PTGS2	TRCN0000045533	A	6	GCTGAATTTAACACCCTCTAT
PTGS2	TRCN0000045534	A	7	GCAGATGAAATACCAAGTCTTT
PTGS2	TRCN0000045535	A	8	CCAGGGCTCAAACATGATGTT
PTGS2	TRCN0000045536	A	9	CGTTGTGAATAACATTCCCTT
PTGS2	TRCN0000045537	A	10	CCATTCTCCTTGAAGGACTT

Clones in boldface were used for the experiments.